- Home
- PAYC vs MRNA Comparison
PAYC vs MRNA Comparison
Compare PAYC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- MRNA
- Stock Information
- Founded
- PAYC 1998
- MRNA 2010
- Country
- PAYC United States
- MRNA United States
- Employees
- PAYC N/A
- MRNA N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAYC Technology
- MRNA Health Care
- Exchange
- PAYC Nasdaq
- MRNA Nasdaq
- Market Cap
- PAYC 12.8B
- MRNA 10.9B
- IPO Year
- PAYC 2014
- MRNA 2018
- Fundamental
- Price
- PAYC $234.04
- MRNA $27.12
- Analyst Decision
- PAYC Hold
- MRNA Hold
- Analyst Count
- PAYC 11
- MRNA 20
- Target Price
- PAYC $234.80
- MRNA $42.41
- AVG Volume (30 Days)
- PAYC 707.4K
- MRNA 8.4M
- Earning Date
- PAYC 08-06-2025
- MRNA 08-01-2025
- Dividend Yield
- PAYC 0.67%
- MRNA N/A
- EPS Growth
- PAYC N/A
- MRNA N/A
- EPS
- PAYC 7.40
- MRNA N/A
- Revenue
- PAYC $1,959,900,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PAYC $10.03
- MRNA N/A
- Revenue Next Year
- PAYC $9.17
- MRNA $10.17
- P/E Ratio
- PAYC $31.60
- MRNA N/A
- Revenue Growth
- PAYC 10.21
- MRNA N/A
- 52 Week Low
- PAYC $153.08
- MRNA $23.15
- 52 Week High
- PAYC $267.76
- MRNA $86.80
- Technical
- Relative Strength Index (RSI)
- PAYC 55.86
- MRNA 43.83
- Support Level
- PAYC $222.91
- MRNA $26.01
- Resistance Level
- PAYC $229.31
- MRNA $28.59
- Average True Range (ATR)
- PAYC 7.22
- MRNA 1.05
- MACD
- PAYC 1.11
- MRNA -0.02
- Stochastic Oscillator
- PAYC 57.88
- MRNA 55.32
About PAYC Paycom Software Inc.
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.